Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
A separate analysis done at Virginia Commonwealth University of more than 841,000 patients with stage 1, 2, or 3 breast cancer, also showed that at five and 10 years after treatment, the women who had been taking GLP-1 drugs had a stunning 60% lower death rate from any cause compared to non-GLP-1 users
Weight changes became more significant over time
Since these medications were initially designed for diabetes, many studies have proven their long-term safety
According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans
However, no large-scale RCT has tested the combined injectable formulation for weight loss
US$ 21.95
US$ 22.66
US$ 25.61
US$ 20.23
US$ 25.74
